Used in targeted cancer therapies, particularly for tumors overexpressing EGFR such as non-small cell lung cancer, colorectal cancer, and head and neck cancers. Functions by binding to the extracellular domain of EGFR, inhibiting receptor activation and downstream signaling pathways involved in cell proliferation and survival. Employed in research settings to validate EGFR expression and in clinical development as a therapeutic candidate. Also serves as a reference standard in antibody comparability studies and biosimilar development.